NIH VideoCast - Comparative Effectiveness and Personalized Medicine: An Essential Interface (Day 2)

Skip Navigation

Comparative Effectiveness and Personalized Medicine: An Essential Interface (Day 2)

Loading... Loading video...

Air date:	Wednesday, October 20, 2010, 8:00:00 AM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 146 * This only includes stats from October 2011 and forward.
Category:	Conferences
Runtime:	04:29:38
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	A conference on the status of comparative effectiveness research and its use in policy and practice. The senior leadership of ECRI Institute1, NIH, AHRQ, the Kaiser Permanente Institute for Health Policy, Health Affairs, the Milbank Memorial Fund, and the Leonard Davis Institute of Health Economics at the University of Pennsylvania invite you to a major conference on the interface between personalized medicine and comparative effectiveness research. This meeting will be convened on October 19th and 20th, 2010, on the campus of the National Institutes of Health in Bethesda, Maryland. Drs. Francis Collins, Director of NIH, and Carolyn Clancy, Director of AHRQ, are among our many distinguished presenters. The conference sessions, over a day and a half, are designed to be understandable and useful to a range of healthcare constituencies. The agenda will have significant time devoted to dialog with the audience and for you to meet the speakers. With the advent of healthcare reform, our nation will be embarking on an unprecedented effort to determine which health care intervention works best for the treatment of a given condition or disorder. The Patient Protection and Affordable Care Act emphasizes the importance of comparative effectiveness research in order to evaluate clinical outcomes across study populations. It also acknowledges the key role of personalized medicine in ensuring the capacity to identify both individual and subgroup differences within populations. The addition of personalized medicine will help clinicians and patients better predict which intervention will deliver the optimal treatment to the appropriate patient at the right time. This meeting explores two critical streams of scientific inquiry in order to better align evidentiary, infrastructure and database needs, to highlight research challenges, and to brainstorm about regulatory, ethical and societal factors affecting both fields. Our aim is to forge new synergies capable of generating innovation in the course of healthcare reform which will result in enhanced health outcomes for the American people.

NLM Title:	Comparative effectiveness and personalized medicine : an essential interface / National Institutes of Health, Agency for Healthcare Research and Quality, ECRI Institute.
Author:	United States. Agency for Healthcare Research and Quality.
Publisher:
Abstract:	(CIT): A conference on the status of comparative effectiveness research and its use in policy and practice. The senior leadership of ECRI Institute1, NIH, AHRQ, the Kaiser Permanente Institute for Health Policy, Health Affairs, the Milbank Memorial Fund, and the Leonard Davis Institute of Health Economics at the University of Pennsylvania invite you to a major conference on the interface between personalized medicine and comparative effectiveness research. This meeting will be convened on October 19th and 20th, 2010, on the campus of the National Institutes of Health in Bethesda, Maryland. Drs. Francis Collins, Director of NIH, and Carolyn Clancy, Director of AHRQ, are among our many distinguished presenters. The conference sessions, over a day and a half, are designed to be understandable and useful to a range of healthcare constituencies. The agenda will have significant time devoted to dialog with the audience and for you to meet the speakers. With the advent of healthcare reform, our nation will be embarking on an unprecedented effort to determine which health care intervention works best for the treatment of a given condition or disorder. The Patient Protection and Affordable Care Act emphasizes the importance of comparative effectiveness research in order to evaluate clinical outcomes across study populations. It also acknowledges the key role of personalized medicine in ensuring the capacity to identify both individual and subgroup differences within populations. The addition of personalized medicine will help clinicians and patients better predict which intervention will deliver the optimal treatment to the appropriate patient at the right time. This meeting explores two critical streams of scientific inquiry in order to better align evidentiary, infrastructure and database needs, to highlight research challenges, and to brainstorm about regulatory, ethical and societal factors affecting both fields. Our aim is to forge new synergies capable of generating innovation in the course of healthcare reform which will result in enhanced health outcomes for the American people.
Subjects:	Comparative Effectiveness Research Precision Medicine
Publication Types:	Congress Webcast
NLM Classification:	WB 102
NLM ID:	101549204
CIT Live ID:	9703
Permanent link:	https://videocast.nih.gov/watch=9703

Related Videos...